M6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Mar 22

PMID 33748145

Citations 72

Authors

Huaying Zhao

Yue Xu

Yilin Xie

Lan Zhang

Ming Gao

Shenglei Li

Feng Wang

Affiliations

Soon will be listed here.

Abstract

N6 methyladenosine (m6A) RNA methylation regulators play an important role in the development of tumors. However, their function in esophageal cancer (EC) has not been fully elucidated. Here, we analyzed the gene expression data of 24 major m6A RNA methylation regulators from 775 patients with EC from TCGA dataset. The present study showed the aberrations of m6A regulators in genome were correlated to prognosis in human ECs. Meanwhile, 17 m6A regulators showed increased expression in EC samples, including YTHDC1, IGF2BP2, FTO, METTL14, YTHDF3, RBM15, WTAP, HNRNPA2B1, HNRNPC, ALKBH5, YTHDF2, METTL16, IGF2BP3, VIRMA, RBM15B, YTHDF1, KIAA1429, HAKAI, and ZC3H13. Among them, we found HNRNPC, YTHDC2, WTAP, VIRMA, IGF2BP3, and HNRNPA2B1 were significantly correlated to worse outcomes and advanced stage in EC. Furthermore, we showed levels of m6A regulators is correlated with the expression of Immuno-regulators (Immunoinhibitors, Immunostimulators, and MHC molecules) and immune infiltration levels in EC. Bioinformatics further confirm m6A regulators were involved in regulating RNA splicing, RNA stability, and cell proliferation. Our study showed m6A regulators are promising targets and biomarkers for cancer immunotherapy in EC.

Citing Articles

WTAP-Mediated N6-Methyladenosine Modification Promotes Gastric Cancer Progression by Regulating MAP2K6 Expression.

Han S, Jiang H, Wang J, Li C, Liu T, Xuan M J Cancer. 2025; 16(5):1420-1437.

PMID: 39991580 PMC: 11843227. DOI: 10.7150/jca.98559.

Beyond destruction: emerging roles of the E3 ubiquitin ligase Hakai.

Escuder-Rodriguez J, Rodriguez-Alonso A, Jove L, Quiroga M, Alfonsin G, Figueroa A Cell Mol Biol Lett. 2025; 30(1):9.

PMID: 39833727 PMC: 11749156. DOI: 10.1186/s11658-025-00693-y.

Detecting the Tumor Prognostic Factors From the YTH Domain Family Through Integrative Pan-Cancer Analysis.

Zhu C, Yang Q, Mu X, Zhai Y, Zhao W, Yin Z Cancer Inform. 2024; 23:11769351241300030.

PMID: 39553336 PMC: 11569503. DOI: 10.1177/11769351241300030.

Interplay of RNA mA Modification-Related Geneset in Pan-Cancer.

Zhang B, Hao Y, Liu H, Wu J, Lu L, Wang X Biomedicines. 2024; 12(10).

PMID: 39457524 PMC: 11504890. DOI: 10.3390/biomedicines12102211.

Qu X, Zhang Y, Li H, Tan Y Transl Cancer Res. 2024; 13(9):4714-4735.

PMID: 39430855 PMC: 11483456. DOI: 10.21037/tcr-24-499.

References

Dai F, Wu Y, Lu Y, An C, Zheng X, Dai L . Crosstalk between RNA mA Modification and Non-coding RNA Contributes to Cancer Growth and Progression. Mol Ther Nucleic Acids. 2020; 22:62-71. PMC: 7486578. DOI: 10.1016/j.omtn.2020.08.004. View

Wu X, Ke X, Ni Y, Kuang L, Zhang F, Lin Y . Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. J Immunol Res. 2021; 2020:8884683. PMC: 7785377. DOI: 10.1155/2020/8884683. View

Liang H, Fan J, Qiao Y . Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 2017; 14(1):33-41. PMC: 5365188. DOI: 10.20892/j.issn.2095-3941.2016.0093. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Gu C, Huang Z, Chen X, Liu C, Rocco G, Zhao S . TEAD4 promotes tumor development in patients with lung adenocarcinoma via ERK signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(12):165921. DOI: 10.1016/j.bbadis.2020.165921. View

Huang G, Wu Q, Zheng Z, Shao T, Chen Y, Zeng W . M6A-related bioinformatics analysis reveals that HNRNPC facilitates progression of OSCC via EMT. Aging (Albany NY). 2020; 12(12):11667-11684. PMC: 7343469. DOI: 10.18632/aging.103333. View

Bi Z, Liu Y, Zhao Y, Yao Y, Wu R, Liu Q . A dynamic reversible RNA N -methyladenosine modification: current status and perspectives. J Cell Physiol. 2019; 234(6):7948-7956. DOI: 10.1002/jcp.28014. View

Zhang Y, Chen W, Pan T, Wang H, Zhang Y, Li C . LBX2-AS1 is activated by ZEB1 and promotes the development of esophageal squamous cell carcinoma by interacting with HNRNPC to enhance the stability of ZEB1 and ZEB2 mRNAs. Biochem Biophys Res Commun. 2019; 511(3):566-572. DOI: 10.1016/j.bbrc.2019.02.079. View

Malhotra G, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C . Global trends in esophageal cancer. J Surg Oncol. 2017; 115(5):564-579. DOI: 10.1002/jso.24592. View

10.

Unberath P, Knell C, Prokosch H, Christoph J . Developing New Analysis Functions for a Translational Research Platform: Extending the cBioPortal for Cancer Genomics. Stud Health Technol Inform. 2019; 258:46-50. View

11.

Baba Y, Nomoto D, Okadome K, Ishimoto T, Iwatsuki M, Miyamoto Y . Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020; 111(9):3132-3141. PMC: 7469863. DOI: 10.1111/cas.14541. View

12.

Chen M, Nie Z, Wen X, Gao Y, Cao H, Zhang S . m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer. Biosci Rep. 2019; 39(12). PMC: 6923333. DOI: 10.1042/BSR20192892. View

13.

Sun S, Han Q, Liang M, Zhang Q, Zhang J, Cao J . Downregulation of m A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non-small cell lung cancer. Thorac Cancer. 2020; 11(11):3269-3279. PMC: 7606000. DOI: 10.1111/1759-7714.13667. View

14.

Yang N, Ying P, Tian J, Wang X, Mei S, Zou D . Genetic variants in m6A modification genes are associated with esophageal squamous-cell carcinoma in the Chinese population. Carcinogenesis. 2020; 41(6):761-768. DOI: 10.1093/carcin/bgaa012. View

15.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

16.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

17.

Salem M, Puccini A, Xiu J, Raghavan D, Lenz H, Korn W . Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist. 2018; 23(11):1319-1327. PMC: 6291329. DOI: 10.1634/theoncologist.2018-0143. View

18.

Qian J, Gao J, Sun X, Cao M, Shi L, Xia T . KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene. 2019; 38(33):6123-6141. DOI: 10.1038/s41388-019-0861-z. View

19.

Shi X, Cheng L, Jiao X, Chen B, Li Z, Liang Y . Rare Copy Number Variants Identify Novel Genes in Sporadic Total Anomalous Pulmonary Vein Connection. Front Genet. 2018; 9:559. PMC: 6265481. DOI: 10.3389/fgene.2018.00559. View

20.

Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou Y . mA regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020; 19(1):53. PMC: 7066851. DOI: 10.1186/s12943-020-01170-0. View